Veradermics, Incorporated: updates and filings

MANENYSEHealthcare · Pharmaceutical Preparations

Price

$125.64

November 17, 2026Market cap $5.3B

What Ploutos Investor adds for Veradermics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 2 fiscal years, from 2024
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 30, 2026 latest annualNov 10, 2026 latest quarterly
  • Nov 13, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 10, 2026Results of operations
    Form8-K
  • Nov 9, 2026Regulation FD disclosure, other material events
    Form8-K
  • Oct 19, 2026Regulation FD disclosure, other material events
    Form8-K
  • Oct 13, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 21, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Aug 14, 2026Filing
    FormEFFECT
  • Aug 14, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Aug 14, 2026Filing (amendment)
    Form144/A
  • Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 11, 2026Results of operations
    Form8-K
  • Aug 7, 2026Filing
    FormS-1
  • Aug 6, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 15, 2026Regulation FD disclosure, other material events
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Filing
    FormD
  • May 12, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 12, 2026Results of operations
    Form8-K
  • May 7, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 5, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • May 5, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • May 5, 2026Over-5% holder statement (active)
    FormSCHEDULE 13D
  • May 1, 2026Material agreement entered, unregistered sale of shares
    Form8-K
  • Apr 29, 2026Filing
    FormEFFECT

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Oct 9, 2020.

The full analysis

What do Veradermics's filings show?

The filings are where every one of Veradermics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.